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Abstract
Background: Patients with hormone receptor-positive breast cancer typically show favorable survival. However, identifying
individuals at high risk of recurrence among these patients is a crucial issue. We tested the hypothesis that [18F]-
fluorodeoxyglucose positron emission tomography (FDG-PET) scans can help predict prognosis in patients with hormone
receptor-positive breast cancer.
Methods: Between April 2004 and December 2008, 305 patients with hormone receptor-positive breast cancer who
underwent FGD-PET were enrolled. Patients with luminal B subtype were identified by positivity for human epidermal
growth factor receptor-2 (HER2) or high Ki67 ($14%) according to criteria recently recommended by the St. Gallen panelists.
The cut-off value of SUVmax was defined using the time-dependent receiver operator characteristic curve for recurrence-free
survival (RFS).
Results: At a median follow up of 6.23 years, continuous SUVmax was a significant prognostic factor with a hazard ratio (HR)
of 1.21 (p= 0.021). The cut-off value of SUVmax was defined as 4. Patients with luminal B subtype (n= 82) or high SUVmax
(n= 107) showed a reduced RFS (p= 0.031 and 0.002, respectively). In multivariate analysis for RFS, SUVmax carried
independent prognostic significance (p= 0.012) whereas classification with immunohistochemical markers did not
(p= 0.274). The Harell c-index was 0.729. High SUVmax was significantly associated with larger tumor size, positive nodes,
HER2 positivity, high Ki67 ($14%), high tumor grade, and luminal B subtype.
Conclusions: Among patients with hormone receptor-positive breast cancer, FDG-PET can help discriminate patients at
high risk of tumor relapse.
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Introduction
In patients with hormone receptor (HR)-positive breast cancer,
which accounts for approximately 75% of breast cancers [1],
endocrine therapies targeting the estrogen receptor (ER) or
estrogen synthesis have reduced annual recurrences by 41% and
deaths by 34%. Nevertheless, treatment failure still occurs in 30%
of patients who are treated with tamoxifen [2], therefore
identifying patients with a poor prognosis among those with
HR-positive breast cancer has become a critical issue in clinical
field. Recent advances in molecular studies based on gene
expression profiling have classified subtypes of breast cancer and
suggest that HR-positive breast cancer is a clinically and
biologically heterogeneous entity [3,4]. These studies identified
at least two major groups of HR-positive tumors, known as
luminal A and B. Identification of luminal B tumors among HR-
positive cancers using immunohistochemical (IHC) markers has
become accepted in clinical practice [5,6], however, debate against
current classification based on IHC markers still remains.
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[18F] fluorodexoyglucose positron emission tomography (FDG-
PET) is a well-established imaging tool for the diagnosis and
staging of various malignancies [7]. In addition, the degree of
FDG uptake can reflect the biologic characteristics of a tumor and
is a validated prognostic factor in various malignancies [8,9]. In
breast cancer, it is well known that ER-positive tumors are
characterized by rather low FDG uptake. Previous studies suggest
that high FDG uptake is correlated with negative estrogen
receptor (ER) expression, negative progesterone receptor (PR)
expression, positive human epidermal growth factor receptor-2
(HER-2) expression, high histologic grade, and high proliferative
marker such as Ki67 [10–12].
Therefore, among ER-positive breast cancer, tumors with
increased FDG uptake can be considered to show more aggressive
behavior than tumors with decreased uptake. Here, we tested the
hypothesis that FDG-PET can help predict prognosis in patients
with hormone receptor-positive breast cancer.
Materials and Methods
Patient selection
Between January 2004 and December 2008, 835 consecutive
women underwent surgery for breast cancer. Of these 835
patients, 682 had undergone preoperative FDG-PET. Patients
were excluded on the basis of the following criteria: known
bilateral breast cancer (n = 28); preoperative chemotherapy,
because chemotherapy can affect tumor characteristics related
with FDG uptake (n = 65); ductal carcinoma in situ (n = 83); and
distant metastases at initial assessment (n = 41). Among these
patients, 309 women with ER-positive and/or PR-positive tumors
were identified.
These HR-positive patients were classified as two intrinsic
subtypes according to criteria recently recommended by the St.
Gallen panelists [5,6]. The Ki67 cut-off value of 14% also adhered
to these criteria. Two subtypes were defined as follows: luminal A
(ER-positive and/or PR-positive, HER2-negative and Ki-67,
14%); or luminal B (ER-positive and/or PR-positive, HER2-
negative, and Ki-67$14%, or ER-positive and/or PR-positive
and HER2-positive, irrespective of Ki67 index). Patients missing
data for any IHC marker were excluded (n = 2). Patients with an
IHC score of 2+ for HER2 but without fluorescence in situ
hybridization (FISH) results for HER2 amplification were also
excluded (n= 2). Data for the remaining 305 patients were entered
into the analysis (Figure S1).
For IHC evaluation of four markers, formalin-fixed paraffin-
embedded tissue sections obtained from surgical specimens were
stained with appropriate antibodies for ER (Novocastra, Newcastle
upon Tyne, UK), PR (Novocastra), HER2 (Ventana Medical
Systems, Tucson, AZ, USA), and Ki-67 (MIB-1; Dako, Glostrup,
Denmark). ER and PR were determined by nuclear staining,
which was graded from 0 to 8 using the Allred score [13]. The
results were categorized as positive when the total score, expressed
as the sum of the proportion score and intensity score, was 3 or
greater. For HER2 evaluation, membranous staining was graded
as 0, 1+, 2+, or 3+ [14]. HER2 status was deemed to be positive
for a score of 3+ and negative for a score of 0 or 1+. Tumors with a
score of 2+ were sent for FISH analysis using the PathVysion
HER2 DNA Probe Kit (Abbott-Vysis, Des Plaines, IL, USA).
Staging was performed according to the American Joint
Committee on Cancer (AJCC), 7th edition. The modified Scarf-
Bloom-Richardson grading system was used for tumor grading.
Adjuvant systemic therapy and/or radiotherapy were considered
according to the standard guidelines based on patient age, primary
tumor characteristics, and axillary lymph node status. Endocrine
therapy was delivered to all patients. The institutional review
board (IRB) of Gangnam Severance Hospital, Yonsei University,
Seoul, Korea, approved the study in accordance with good clinical
practice guidelines and the Declaration of Helsinki. The IRB
waived the need for written informed consent from the partici-
pants because of the retrospective design.
FDG-PET method
Prior to FDG-PET, each patient fasted for a minimum of 8
hours and blood glucose level was controlled to lower than
130 mg/dl. Patients received an intravenous injection of 0.14 mCi
MBq 18F-FDG in the arm contralateral to the primary tumor. At
60 min after injection of 18F-FDG, whole-body emission scans
were obtained using a Philips Allegro PET camera (Philips
Medical Systems, Cleveland, Ohio, USA). All patients were
studied in the supine position with their arms raised. Attenuation-
corrected transaxial images were reconstructed with an iterative
transmission algorithm called a row-action maximum likelihood
3D protocol using a 3D image filter into a 1286128 matrix. For
semi-quantitative evaluation, SUVmax was calculated by measur-
ing the absorption of 18F-FDG by tumors in the region of interest
(ROI) as follows:
SUVmax= [maximal radioactivity concentration in ROI (mCi/
g)/injected dose (mCi)/patient’s weight (kg)].
Statistical analysis
Age was presented as median value with range and compared
by Mann–Whitney U test. Discrete variables were compared by
chi-square test. The cut-off point of SUVmax was defined using the
time-dependent ROC curve for recurrence-free survival (RFS).
The primary end-point was RFS. RFS was measured from the
date of the first curative surgery to the date of the first loco-
regional recurrence or distant metastasis. The Kaplan-Meier
method was used to estimate the RFS, and the estimated survival
curves were compared using the log-rank test. Significant
prognostic factors associated with recurrence-free survival were
selected using Harrell c-statistic [15] and a Cox proportional
hazard regression model was applied for multivariate survival
analysis. Student’s t-tests were conducted to compare SUVmax
according to subtype or prognostic factors. All analyses were
performed using SPSS version 18 (SPSS; Chicago, IL) and R
(http://www.r-projet.org). Statistical significance was defined by a
P-value,0.05 or a 95% confidence interval (CI) that did not
include 1.
Results
Patients’ characteristics
Table 1 shows patient characteristics according to the intrinsic
subtypes (luminal A and luminal B). The two groups did not differ
significantly in T stage, N stage, and AJCC stage, representing
tumor burden, or in ER and PR status. In contrast, median age of
the luminal A subgroup was significantly higher than that of the
luminal B subgroup whereas histologic grade was significantly
higher in luminal B than in luminal A. Furthermore, median
SUVmax was significantly higher in luminal B than in luminal A
(4.7 vs. 2.6, respectively). There were no significant differences in
adjuvant treatments except for adjuvant endocrine treatment. The
higher rate of tamoxifen use in the luminal B subgroup suggested
that more premenopausal women were classified as luminal B and
was concordant with the lower median age of patients with the
luminal B subtype.
PET in HR-Positive Breast Cancer
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Table 1. Baseline characteristics of patients according to intrinsic subtypes.
Characteristics All patients (n=305) Luminal A (n=223) Luminal B (n=82) P-valuea
Age years, median (range) 48 (25–80) 48 (28–80) 45 (25–80) 0.019b
T stage 0.127
T1 174 (57) 135 (60) 39 (48)
T2 128 (41) 86 (39) 42 (51)
T3 3 (2) 2 (1) 1 (1)
N stage 0.367
N0 201 (66) 146 (65) 55 (67)
N1 81 (27) 63 (28) 18 (22)
N2 17 (5) 11 (5) 6 (7)
N3 6 (2) 3 (1) 3 (4)
AJCC stage 0.284
I 126 (41) 98 (44) 28 (34)
II 155 (51) 109 (49) 46 (56)
III 24 (8) 16 (7) 8 (10)
Histologic gradec ,0.001
1 129 (42) 112 (50) 17 (27)
2 117 (38) 83 (37) 34 (41)
3 26 (9) 0 (0) 26 (32)
Estrogen receptor 0.507
Positive 277 (91) 204 (91) 73 (89)
Negative 28 (9) 19 (9) 9 (11)
Progesterone receptor 0.331
Positive 266 (87) 197 (88) 69 (84)
Negative 39 (13) 26 (12) 13 (16)
HER2 ,0.001
Positived 47 (15) 0 (0) 47 (57)
Negative 258 (85) 223 (100) 35 (43)
Ki67 ,0.001
High 33 (11) 0 (0) 33 (40)
Low 272 (89) 223 (100) 49 (60)
SUVmax ,0.001
b
Median (range) 3.1 (0.8–12.8) 2.6 (0.8–12.8) 4.7 (1.0–11.2)
Adjuvant endocrine therapy 0.030
Tamoxifen 129 (42) 85 (38) 44 (54)
Toremifene 62 (20) 44 (20) 18 (22)
Letrozole 61 (20) 49 (22) 12 (15)
Anastrozole 53 (18) 45 (20) 8 (9)
Adjuvant chemotherapy 0.146
Yes 187 (61) 131 (59) 56 (68)
No 118 (39) 92 (41) 26 (32)
Adjuvant radiotherapy 0.999
Yes 119 (39) 87 (39) 32 (39)
No 186 (61) 136 (61) 50 (61)
AJCC, American Joint Committee on Cancer; SUVmax, maximum standardized uptake value; HER2, human epidermal growth factor receptor-2.
a Chi-square test, except for bMann–Whitney U test.
c Data with missing values.
d HER-2 positivity was defined by 3+ score on immunohistochemistry or amplification on fluorescence in situ hybridization.
doi:10.1371/journal.pone.0105905.t001
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Survival analysis with SUVmax
At a median follow up of 6.12 years there were 17 recurrences:
5 loco-regional and 12 distant metastases. First, we performed
univariate analysis using continuous SUVmax. This analysis
showed that continuous SUVmax was a significant prognostic
factor with a hazard ratio (HR) of 1.21 (P=0.018; 95% CI, 1.03–
1.42). Next, we determined the cut-off point of SUVmax using the
time-dependent ROC curve in relation to RFS, which yielded an
area under the curve (AUC) of 0.721 (95% CI, 0.594–0.884;
Fig. 1). Youden’s index was highest for SUVmax of 4.1. With
consideration of clinical application, we defined the cut-off for
SUVmax as 4, which gave an AUC for RFS of 0.731 (95% CI,
0.592–0.902). Subsequently, high and low SUVmax groups were
defined by a cut-off value of 4. Based on univariate analysis, the
RFS time differed significantly between groups stratified by
SUVmax (SUVmax,4 versus$4; P=0.002; Fig. 2A).
In univariate analyses using other characteristics (Table S1),
RFS differed significantly between groups stratified by age (#35
vs. .35 years; P,0.001), intrinsic subtype (luminal A vs. luminal
B; P=0.031; Fig. 2B), and PR (positive vs. negative; P=0.003).
SUVmax versus intrinsic subtypes
Kaplan-Meier plots comparing groups stratified by SUVmax and
intrinsic subtype are presented in Fig. 3. RFS did not differ
significantly according to subtype within the group of low SUVmax
(group 1 vs. group 2; P=0.315, log-rank test) or the group of high
SUVmax (group 3 vs. group 4; P=0.060, log-rank test). In contrast,
within the group of luminal B, RFS significantly differed according
to SUVmax (group 2 vs. group 4; P=0.018, log-rank test). Within
the group of luminal A, RFS did not differ significantly according
to SUVmax (group 1 vs. group 3; P=0.280, log-rank test).
Multivariate analysis
Multivariate analysis using a Cox regression hazard model
suggested that high SUVmax (adjusted HR 4.09; 95% CI 1.36–
12.31) was an independent prognostic factor for RFS, and age less
than 35 (adjusted HR 7.09; 95% CI 2.56–19.60) and negative PR
status (adjusted HR 4.47; 95% CI 1.61–12.44) were associated
with an increased risk of tumor recurrence (Table 2). However,
the intrinsic subtype was not a prognostic factor in multivariate
analysis (P=0.240). For this model, the Harrell c-index was 0.729.
In addition, among patients who received adjuvant chemotherapy
(n= 187), dichotomized SUVmax was repeatedly shown to be an
independent prognostic factor for RFS (adjusted HR 5.96; 95% CI
1.49–23.95; Table S2). The Harrell c-index was 0.741 in this
model.
SUVmax according to tumor characteristics
The mean SUVmax in the two groups was compared after
stratification by tumor characteristics (Table 3). The mean
SUVmax was significantly higher for the following prognostic
factors: large tumor size (P,0.001), positive lymph node
(P=0.011), positive HER2 (P,0.001), high Ki67 (P=0.011),
and high histologic grade (P,0.001), all of which are considered
risk factors. In addition, the mean SUVmax of the luminal B
subtype was significantly higher than that of luminal A.
Discussion
In this genomic era, molecular profiling of breast cancer has
enhanced our understanding of the complexity and heterogeneity
of breast cancer [4]. To translate this understanding of intrinsic
subtypes into clinical practice, IHC expression patterns have been
widely investigated as surrogate markers. The experts of the St.
Gallen’s panel recommended optimal guidelines for intrinsic
subtyping based on IHC markers [5,6]. In our study, we used these
criteria to identify the intrinsic subtypes of HR-positive tumors.
In terms of prognostic discrimination of endocrine-responsive
breast cancer, our results suggested that SUVmax is superior to
classification based on surrogate IHC markers. SUVmax demon-
strated independent prognostic significance in multivariate analysis
whereas classification with IHC markers did not. Analysis revealed
that our model including SUVmax had good predictive value for
RFS, with a Harell c-index of 0.729. These findings suggest a
potential role for FDG-PET in better predicting groups with poor
and good prognosis among patients with HR-positive breast
cancer.
It is known that HR-positive tumors show lower SUVmax than
HR-negative tumors [10–12]. Regarding intrinsic subtypes,
SUVmax was lowest in the luminal A subtype and higher in
HER2 and triple negative subtypes [16,17]. The increased
accumulation of FDG observed in the high SUVmax tumors
Figure 1. Time-dependent ROC curve for recurrence-free survival (n =305).
doi:10.1371/journal.pone.0105905.g001
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reflects highly proliferating and poorly differentiated cancer.
Therefore, HR-positive tumors with high SUVmax might have
aggressive behavior and show a propensity for high proliferation.
Indeed, our findings suggested that SUVmax is associated with high
Ki67, HER2 positivity, and higher histologic grade, even in HR-
positive cancer (Table 3).
To evaluate tumor proliferation based on PET scans, PET
imaging using 18F-fluorothymidine (FLT) has been investigated in
breast cancer [18,19]. FLT-PET is known to be closely associated
with Ki67 expression in breast cancer. Although high SUVmax of
FDG-PET correlated with high Ki67 in our study, FLT-PET is
recognized as a better tool than FDG-PET in terms of evaluation
of tumor proliferation. FLT-PET was not available for our study,
but it will be interesting to compare the prognostic significance of
FDG-PET with that of FLT-PET in HR-positive tumors.
Interestingly, in the analysis with combined factor using
SUVmax and intrinsic subtypes (Figure 3), we noted that Group
4 had higher proportion of HER2-positive tumors than group 2
(Figure S2). As suggested in Table 3, SUVmax was higher in
HER2-positive tumor, thus it seems reasonable that luminal B
tumors with high SUVmax (Group 4) had a higher HER2-positive
rate than luminal B tumors with low SUVmax (Group 2). It is
concordant with previous studies that most of HER2-positive
luminal B had a higher chance of tumor recurrence among
hormone receptor-positive tumors [20,21]. In addition, it is
noteworthy that there might be tumors with good prognosis even
in HER2-positive luminal B tumors and those tumors can be
identified by SUVmax.
Recent studies suggested that PR status should be considered as
a critical prognosticator in HR-positive women [22–24]. Prog-
nostic power of PR is also recognized by the panels of St. Gallen in
2013 [5]. Our data confirm the prognostic significance of PR. The
reproducibility of previous findings implied that our cohort
showed a reliable outcome and the quality of IHC markers was
well controlled. Furthermore, our data suggest that SUVmax
remains a good prognostic marker for HR-positive breast cancer
independent of PR.
The limitations of our study reflect its retrospective nature and
the heterogeneity of the patient population. One important factor
is the inability to control for variations in adjuvant treatments that
may influence survival outcomes. Therefore, to minimize the
confounding effect of adjuvant treatment, we performed the same
analyses in patients with adjuvant chemotherapy. These analyses
revealed that SUVmax still carried prognostic significance for RFS
in patients receiving both adjuvant chemotherapy and endocrine
therapy.
Despite these limitations, our study highlights the prognostic
impact of FDG-PET for patients with HR-positive breast cancer.
The prognostic implications of SUVmax observed in our study
warrant further investigation in prospective studies.
Figure 2. Kaplan-Meier plots for recurrence-free survival. All P-values are calculated by the log-rank test (A) Stratification by SUVmax (P= 0.002)
(B) Stratification by the intrinsic subtypes (P= 0.032).
doi:10.1371/journal.pone.0105905.g002
Figure 3. Kaplan-Meier plots stratified by combined factors
with SUVmax and the intrinsic subtype: Group 1, low SUVmax
and luminal A (n=163); Group 2, low SUVmax and luminal B
(n=35); Group 3, high SUVmax and luminal A (n=60); Group 4,
high SUVmax and luminal B (n=47). P-value calculated by the log-
rank test was 0.001.
doi:10.1371/journal.pone.0105905.g003
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Table 2. Multivariate analysis using Cox regression hazard model for recurrence-free survival.
Characteristicsa P-value Adjusted HR 95% confidence interval
Age, years ,0.001
.35 (n= 27) reference
#35 (n= 278) 7.09 2.56–19.60
Progesterone receptor 0.004
Positive (n= 266) reference
Negative (n= 39) 4.47 1.61–12.44
Intrinsic subtype 0.274
Luminal A (n= 223) reference
Luminal B (n= 82) 1.77 0.64–4.90
SUVmax 0.012
4, (n= 198) reference
$4 (n= 107) 4.09 1.36–12.31
HR, hazard ratio; SUVmax, maximum standardized uptake value.
a Presented variables are selected using Harrell c-statistic. In this analysis, Harrell c-index was 0.729.
doi:10.1371/journal.pone.0105905.t002
Table 3. Comparisons of SUVmax according to tumor characteristics.
Characteristics Mean SUVmax±SD P-value
a
Age, years 0.224
.35 (n= 27) 3.63±2.31
#35 (n= 278) 4.43±3.28
Tumor size ,0.001
#2 cm (n= 174) 4.72±2.60
.2 cm (n= 131) 2.92±1.94
Lymph node status 0.011
Negative (n= 201) 3.44±2.36
Positive (n= 104) 4.18±2.41
Estrogen receptor status 0.928
Positive (n= 277) 3.69±2.43
Negative (n= 28) 3.74±2.33
Progesterone receptor status 0.394
Positive (n= 266) 3.74±2.47
Negative (n= 39) 3.43±2.00
HER2 ,0.001
Negative (n= 258) 3.44±2.33
Positive (n= 47) 5.12±2.40
Ki67 0.011
,14% (n=272) 3.57±2.35
$14% (n=33) 4.70±2.76
Histologic gradeb ,0.001
1 and 2 (n=246) 5.85±2.84
3 (n= 26) 3.58±2.27
Subtype ,0.001
Luminal A (n= 223) 3.22±2.15
Luminal B (n= 82) 4.98±2.64
HER2, human epidermal growth factor receptor-2.
a Student’s t-tests.
b Data with missing values.
doi:10.1371/journal.pone.0105905.t003
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In conclusion, among patients with hormone receptor-positive
breast cancer, FDG-PET can help discriminate patients at high
risk of tumor relapse.
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